Role of the androgen receptor in triple-negative breast cancer

Clinical Advances in Hematology and Oncology

Volumn 14, Issue 3, 2016, Pages 186-193

  Rampurwala, Murtuza ^a   Wisinski, Kari B ^a   O’Regan, Ruth ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Androgen receptor; AR; Bicalutamide; Enzalutamide; TNBC; Triple negative breast cancer

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTHRACYCLINE; ANTIANDROGEN; BICALUTAMIDE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ENZALUTAMIDE; ORTERONEL; RIBOCICLIB; TASELISIB; TESTOSTERONE; ANDROGEN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT;

ADIPOSE TISSUE CELL; ADJUVANT THERAPY; ARTICLE; BREAST EPITHELIUM CELL; CANCER PROGNOSIS; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TARGETING; FIBROBLAST; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; CANCER STAGING; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; PROGNOSIS;

ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84961575305     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-E386.
2. Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). National Cancer Institute. http://seer.can­cer.gov/csr/1975_2009_pops09/. Updated April 2012. Accessed January 29, 2016.
3. American Cancer Society. Cancer Facts & Figures 2015. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/index. Accessed January 29, 2015.
4. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011;16(1):1-11.
5. Boyle P. Triple-negative breast cancer: epidemiological considerations and rec­ommendations. Ann Oncol. 2012;23(6):vi7-vi12.
6. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109(9):1721-1728.
7. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and sur­vival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492-2502.
8. Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, et al. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. 2011;117(16):3658-3669.
9. Gelmon K, Dent R, Mackey JR, Laing K, McLeod D, Verma S. Targeting triple-negative breast cancer: optimising therapeutic outcomes. Ann Oncol. 2012;23(9):2223-2234.
10. Kassam F, Enright K, Dent R, et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer. 2009;9(1):29-33.
11. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
12. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19(2):264-271.
13. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418-8423.
14. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical char­acterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367-5374.
15. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-2767.
16. Masuda H, Baggerly KA, Wang Y, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19(19):5533-5540.
17. Jézéquel P, Loussouarn D, Guérin-Charbonnel C, et al. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Res. 2015;17:43.
18. Yu KD, Zhu R, Zhan M, et al. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clin Cancer Res. 2013;19(10):2723-2733.
19. Barton VN, D’Amato NC, Gordon MA, et al. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Mol Cancer Ther. 2015;14(3):769-778.
20. Birrell SN, Butler LM, Harris JM, Buchanan G, Tilley WD. Disruption of androgen receptor signaling by synthetic progestins may increase risk of develop­ing breast cancer. FASEB J. 2007;21(10):2285-2293.
21. Wilson JD, Griffin JE, Leshin M, George FW. Role of gonadal hormones in development of the sexual phenotypes. Hum Genet. 1981;58(1):78-84.
22. Zhu X, Li H, Liu JP, Funder JW. Androgen stimulates mitogen-activated protein kinase in human breast cancer cells. Mol Cell Endocrinol. 1999;152(1-2):199-206.
23. Peters AA, Buchanan G, Ricciardelli C, et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res. 2009;69(15):6131-6140.
24. Wong YC, Xie B. The role of androgens in mammary carcinogenesis. Ital J Anat Embryol. 2001;106(2)(1):111-125.
25. Eliassen AH, Missmer SA, Tworoger SS, et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst. 2006;98(19):1406-1415.
26. Bratthauer GL, Lininger RA, Man YG, Tavassoli FA. Androgen and estrogen recep­tor mRNA status in apocrine carcinomas. Diagn Mol Pathol. 2002;11(2):113-118.
27. Safarpour D, Pakneshan S, Tavassoli FA. Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified? Am J Cancer Res. 2014;4(4):353-368.
28. Ogawa Y, Hai E, Matsumoto K, et al. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol. 2008;13(5):431-435.
29. Park S, Koo J, Park HS, et al. Expression of androgen receptors in primary breast cancer. Ann Oncol. 2010;21(3):488-492.
30. Kuenen-Boumeester V, Van der Kwast TH, Claassen CC, et al. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer. 1996;32A(9):1560-1565.
31. Moinfar F, Okcu M, Tsybrovskyy O, et al. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer. 2003;98(4):703-711.
32. Vera-Badillo FE, Templeton AJ, de Gouveia P, et al. Androgen receptor expres­sion and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(1):djt319.
33. Thike AA, Yong-Zheng Chong L, Cheok PY, et al. Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. Mod Pathol. 2014;27(3):352-360.
34. McGhan LJ, McCullough AE, Protheroe CA, et al. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. Ann Surg Oncol. 2014;21(2):361-367.
35. McNamara KM, Yoda T, Takagi K, Miki Y, Suzuki T, Sasano H. Androgen recep­tor in triple negative breast cancer. J Steroid Biochem Mol Biol. 2013;133:66-76.
36. Gasparini P, Fassan M, Cascione L, et al. Androgen receptor status is a prog­nostic marker in non-basal triple negative breast cancers and determines novel therapeutic options. PLoS One. 2014;9(2):e88525.
37. Gucalp A, Traina TA. Triple-negative breast cancer: role of the androgen recep­tor. Cancer J. 2010;16(1):62-65.
38. Mrklić I, Pogorelić Z, Capkun V, Tomić S. Expression of androgen receptors in triple negative breast carcinomas. Acta Histochem. 2013;115(4):344-348.
39. Hickey TE, Robinson JL, Carroll JS, Tilley WD. Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol. 2012;26(8):1252-1267.
40. Chottanapund S, Van Duursen MB, Navasumrit P, et al. Effect of androgens on different breast cancer cells co-cultured with or without breast adipose fibro­blasts. J Steroid Biochem Mol Biol. 2013;138:54-62.
41. Chavez KJ, Garimella SV, Lipkowitz S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis. 2010;32(1-2):35-48.
42. Doane AS, Danso M, Lal P, et al. An estrogen receptor-negative breast can­cer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 2006;25(28):3994-4008.
43. Cochrane DR, Bernales S, Jacobsen BM, et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014;16(1):R7.
44. Gonzalez LO, Corte MD, Vazquez J, et al. Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer. 2008;8:149.
45. Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ. Androgen recep­tor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol. 2003;120(5):725-731.
46. Riva C, Dainese E, Caprara G, et al. Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma. Virchows Arch. 2005;447(4):695-700.
47. Hu R, Dawood S, Holmes MD, et al. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res. 2011;17(7):1867-1874.
48. Luo X, Shi YX, Li ZM, Jiang WQ. Expression and clinical significance of andro­gen receptor in triple negative breast cancer. Chin J Cancer. 2010;29(6):585-590.
49. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognos­tic markers in triple-negative breast cancer. Cancer. 2007;109(1):25-32.
50. Sutton LM, Cao D, Sarode V, et al. Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triple-negative breast carcinoma. Am J Clin Pathol. 2012;138(4):511-516.
51. Qu Q, Mao Y, Fei XC, Shen KW. The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis. PLoS One. 2013;8(12):e82650.
52. Pistelli M, Caramanti M, Biscotti T, et al. Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. Cancers (Basel). 2014;6(3):1351-1362.
53. Park S, Koo JS, Kim MS, et al. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol. 2011;22(8):1755-1762.
54. Choi JE, Kang SH, Lee SJ, Bae YK. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol. 2015;22(1):82-89.
55. Robinson JL, Macarthur S, Ross-Innes CS, et al. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J. 2011;30(15):3019-3027.
56. Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005;24(29):4660-4671.
57. Lehmann-Che J, Hamy AS, Porcher R, et al. Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. Breast Cancer Res. 2013;15(3):R37.
58. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778-785.
59. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164-172.
60. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275-1281.
61. Loibl S, Müller BM, von Minckwitz G, et al. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2011;130(2):477-487.
62. Huober J, von Minckwitz G, Denkert C, et al. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat. 2010;124(1):133-140.
63. Esserman LJ, Berry DA, Cheang MC, et al; I-SPY 1 TRIAL Investigators. Chemotherapy response and recurrence-free survival in neoadjuvant breast can­cer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012;132(3):1049-1062.
64. US Department of Health and Human Services, Food and Drug Administra­tion, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Pathologic Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval. Washington, DC: US Department of Health and Human Services; October 2014.
65. Perrault DJ, Logan DM, Stewart DJ, Bramwell VH, Paterson AH, Eisen­hauer EA. Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. Invest New Drugs. 1988;6(3):207-210.
66. Zhao TP, He GF. A phase II clinical trial of flutamide in the treatment of advanced breast cancer. Tumori. 1988;74(1):53-56.
67. Gucalp A, Tolaney S, Isakoff SJ, et al; Translational Breast Cancer Research Consortium (TBCRC 011). Phase II trial of bicalutamide in patients with andro­gen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res. 2013;19(19):5505-5512.
68. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787-790.
69. Beer TM, Armstrong AJ, Rathkopf DE, et al; PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424-433.
70. Scher HI, Fizazi K, Saad F, et al; AFFIRM Investigators. Increased sur­vival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-1197.
71. Traina TA, Miller K, Yardley DA, et al. Results from a phase 2 study of enzalu­tamide (enza), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer [ASCO abstract 1003]. J Clin Oncol. 2015;33(15).
72. Parker JS, Peterson A, Tudor JC, et al. A novel biomarker to predict sensitivity to enzalutamide in TNBC [ASCO abstract 1083]. J Clin Oncol. 2015;33(15).
73. Fizazi K, Jones R, Oudard S, et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol. 2015;33(7):723-731.
74. Saad F, Fizazi K, Jinga V, et al; ELM-PC 4 investigators. Orteronel plus pred­nisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol. 2015;16(3):338-348.
75. ClinicalTrials.gov. Orteronel as monotherapy in patients with metastatic breast cancer (MBC) that expresses the androgen receptor (AR). https://clinicaltrials.gov/ct2/show/NCT01990209. Identifier: NCT01990209. Accessed January 29, 2016.
76. Toren PJ, Kim S, Pham S, et al. Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer. Mol Cancer Ther. 2015;14(1):59-69.
77. ClinicalTrials.gov. Open-label study to evaluate the safety, tolerability, pharmaco­kinetics, pharmacodynamics and efficacy of VT-464 in patients with advanced breast cancer. https://clinicaltrials.gov/ct2/show/NCT02580448?term=NCT02580448&rank=1. Identifier: NCT02580448. Accessed January 29, 2016.
78. Lehmann BD, Bauer JA, Schafer JM, et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res. 2014;16(4):406.
79. ClinicalTrials.gov. Taselisib and enzalutamide in treating patients with androgen receptor positive triple-negative metastatic breast cancer. https://clinicaltrials.gov/ct2/results?term=NCT02457910&Search=Search. Identifier: NCT02457910. Accessed January 29, 2016.
80. Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of target­ing cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14(2):130-146.
81. Dickson C, Fantl V, Gillett C, et al. Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer Lett. 1995;90(1):43-50.
82. Dukelow T, Kishan D, Khasraw M, Murphy CG. CDK4/6 inhibitors in breast cancer. Anticancer Drugs. 2015;26(8):797-806.
83. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor pal­bociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25-35.
84. Turner NC, Ro J, André F, et al; PALOMA3 Study Group. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015;373(3):209-219.
85. Asghar U, Herrera-Abreu MT, Cutts R, et al. Identification of subtypes of triple negative breast cancer (TNBC) that are sensitive to CDK4/6 inhibition [ASCO abstract 11098]. J Clin Oncol. 2015;33(15).
86. Korpal M, Korn JM, Gao X, et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov. 2013;3(9):1030-1043.
87. Tripathy D, Bardia A, Hurvitz SA, et al. Phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) in combination with either tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treat­ment of premenopausal women with HR+, HER2– advanced breast cancer (aBC): MONALEESA-7 [ASCO abstract TPS625]. J Clin Oncol. 2015;33(15).
88. ClinicalTrials.gov. Palbociclib in combination with bicalutamide for the treatment of AR+ metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT02605486. Identifier: NCT02605486. Accessed January 29, 2016.